VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

OptimizeRx Executive Compensation (FY25)

OPRX · Waltham, MA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Stephen Silvestro
Latest say-on-pay support
=
June 9, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on OptimizeRx

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 12, 2026
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
OptimizeRx brief$500Get the executive brief
Velarion Intel, one year, every company
188 figures on this page: 182 cited to the filing that reported them, 6 calculated from figures it prints. See the citations

More on OptimizeRx

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Stephen Silvestro: $973,132 → $2,717,717 (179.3% higher)
Say-on-pay support: 58.5% → 92.9% (34.4 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is OptimizeRx's chief executive and what were they paid?
Stephen Silvestro, Chief Executive Officer, received $2,717,717 in total compensation for fiscal 2025. Silvestro's total was 179.3% higher than the $973,132 reported for fiscal 2024.
What was OptimizeRx's say-on-pay result?
Shareholders supported the say-on-pay proposal with 92.9% of votes cast for or against in favor at the meeting held June 9, 2026 for fiscal 2025.
Which companies are in OptimizeRx's peer group?
The disclosed peer group names American Well Corporation, Arteris, Inc., Augmedix, Inc., CareCloud, Inc. and Computer Programs and Systems, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Edward Stelmakh
Chief Financial Officer & Chief Operations Officer
◇◇◇◇——◇◇
Stephen Silvestro
Chief Commercial Officer
◇◇◇◇——◇◇
William Febbo
Chief Executive Officer
◇◇————◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William Febbo
Chief Executive Officer
◇◇◇◇◇—◇◇
Stephen Silvestro
President
◇◇◇◇◇—◇◇
Edward Stelmakh
Chief Financial Officer & Chief Operations Officer
◇◇◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William Febbo
Former Chief Executive Officer
Departed during or after this year
◇—◇———◇◇
Edward Stelmakh
Chief Financial Officer & Chief Operations Officer
◇—◇◇◇—◇◇
Stephen Silvestro
Chief Executive Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stephen Silvestro
Chief Executive Officer
◇—◇◇◇—◇◇
Theresa Greco
Chief Commercial Officer
◇—◇◇◇—◇◇
Edward Stelmakh
Chief Financial & Strategy Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Reserve ProposalOTHER◇—————◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Stephen SilvestroOption◇—◇05/15/2029
Option◇—◇12/22/2029
RSU◇◇——
Option◇—◇08/21/2029
RSU◇◇——
RSU◇◇——
Option◇—◇12/18/2028
RSU◇◇——
Edward StelmakhOption◇—◇12/22/2029
Option◇—◇08/21/2029
RSU◇◇——
RSU◇◇——
Option◇—◇12/18/2028
RSU◇◇——
Theresa GrecoOption◇—◇08/21/2029
Option◇—◇12/22/2029
RSU◇◇——
Option◇—◇05/15/2029
Option◇—◇11/01/2027
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Edward Stelmakh
Chief Financial & Strategy Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Stephen Silvestro
Chief Executive Officer · Severance agreement
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Theresa Greco
Chief Commercial Officer · Severance agreement
Change-in-control base◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
Clawback◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Lynn O'Connor Vos
◇◇————◇
Patrick Spangler
◇◇————◇
Catherine Klema
◇◇————◇
James Lang
◇◇————◇
Gregory Wasson
◇◇————◇
Mariyamma Varghese Presti and Stephen Silvestro served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • American Well Corporation AMWL
  • Arteris, Inc. symbol not shown
  • Augmedix, Inc. AUGX
  • CareCloud, Inc. CCLD
  • Computer Programs and Systems, Inc. symbol not shown
  • CoreCard Corporation CCRD
  • Domo, Inc. DOMO
  • Health Catalyst, Inc. HCAT
  • HealthStream, Inc. HSTM
  • iCAD, Inc. ICAD
  • Intellicheck, Inc. symbol not shown
  • Kaltura, Inc. KLTR
  • Phreesia, Inc. PHR
  • Simulations Plus, Inc. SLP
  • Smith Micro Software, Inc. symbol not shown
  • SoundThinking, Inc. SSTI
  • Viant Technology Inc. VNT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 9, 2026=◇◇◇
2024June 11, 2025=◇◇◇
2023June 5, 2024=◇◇◇
2022June 7, 2023=◇◇◇
2021June 9, 2022=◇◇◇
2020August 19, 2021=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Stephen Silvestro (Chief Executive Officer), FY2025 total compensation $2,717,717 (base salary $500,000) [exec_comp, SEC accession 0001213900-26-049698, filed 2026-04-30]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when OptimizeRx files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact OptimizeRx disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where OptimizeRx sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether OptimizeRx's disclosed peer group is defensible, who names OptimizeRx back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
188 figures on this page: 182 cited to the filing that reported them, 6 calculated from figures it prints.
182 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001213900-26-068272
  2. 0001213900-26-049698
    ADVISORY VOTE ON EXECUTIVE COMPENSATION & · DIRECTOR COMPENSATION
  3. 0001448431-26-000005
    Exhibit
  4. 0001213900-25-054784
  5. 0001213900-25-037114
    Compensation Discussion and Analysis · Summary Compensation Table for 2024
  6. 0001213900-24-050753
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001213900-24-036855
    Summary Compensation Table for Fiscal 2023
  8. 0001213900-23-047179
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001213900-23-032516
    Summary Compensation Table for Fiscal 2022
  10. 0001213900-22-032533
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001213900-21-044810
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “OptimizeRx executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/OPRX (accessed 2026).
Short form: data: Velarion

The paid brief for OptimizeRx

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about OptimizeRx and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers OptimizeRx discloses

The companies named in OPRX's own disclosed peer group.

American Well CorporationAugmedix, Inc.CareCloud, Inc.CoreCard CorporationDomo, Inc.Health Catalyst, Inc.HealthStream, Inc.iCAD, Inc.Kaltura, Inc.Phreesia, Inc.Simulations Plus, Inc.SoundThinking, Inc.Viant Technology Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy